Mechanisms Involved in Heparin-Induced Thrombocytopenia and Associated Thrombosis

被引:0
作者
Vissac, Anne Marie [1 ]
Amiral, Jean [1 ]
机构
[1] HYPHEN BioMed Res, F-95000 Neuville sur Oise, France
关键词
Heparin-induced thrombocytopenia; platelet factor 4-heparin complexes; mechanisms; antibodies; thrombosis;
D O I
10.1055/s-0028-1086078
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin-induced thrombocytopenia (HIT), sometimes complicated by the occurrence of thrombosis (HITT), is a rare but severe complication of heparin therapy (both unfractionated and low molecular weight heparin). It is induced by the generation of antibodies targeted to complexes of platelet factor (PF) 4 and heparin (H), mainly IgG isotypes with the highest avidity. Laboratory studies and clinical surveys help elucidate the Mechanisms of HIT/HITT. The presence of stoichiometric complexes of H-PF4 is probably the immunogenic stimulus that induces the generation of antibodies, via a T-cell response. In pathologies, where a large extent of platelet activation Occurs, especially vicinity complexes can be formed that at the vicinity of pathological sites, large amounts of H-PI, bind to platelet surfaces (mainly activated platelets), but also to endothelial cells and other blood cells such as monocytes. This induces cell-cell interactions and the release of microparticles, which can amplify to a hypercoagulable state resulting from release of tissue factor, microparticles, and expression of procoagulant phospholipids. The clinical consequence is the development of thrombocytopenia, which can be complicated by a rapid evolution to thrombosis that becomes life threatening. The present understanding of the mechanisms of HIT/HITT, the advances in clinical investigations, and the availability of alternative anticoagulants have progressively introduced new tools for a better diagnosis and management of patients with this disease.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 47 条
[1]   Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation [J].
Amiral, J ;
Pouplard, C ;
Vissac, AM ;
Walenga, JM ;
Jeske, W ;
Gruel, Y .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (02) :336-341
[2]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[3]   Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia [J].
Amiral, J ;
MarfaingKoka, A ;
Wolf, M ;
Alessi, MC ;
Tardy, B ;
BoyerNeumann, C ;
Vissac, AM ;
Fressinaud, E ;
Poncz, M ;
Meyer, D .
BLOOD, 1996, 88 (02) :410-416
[4]  
AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21
[5]   Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8 [J].
Arepally, GM ;
Mayer, IM .
BLOOD, 2001, 98 (04) :1252-1254
[6]   PLATELETS PRIME PMN VIA RELEASED PF4 - MECHANISM OF PRIMING AND SYNERGY WITH GM-CSF [J].
AZIZ, KA ;
CAWLEY, JC ;
ZUZEL, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (04) :846-853
[7]   Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia thrombosis [J].
Bacsi, S ;
De Palma, R ;
Visentin, GP ;
Gorski, J ;
Aster, RH .
BLOOD, 1999, 94 (01) :208-215
[8]   Argatroban anticoagulation in critically ill patients [J].
Beiderlinden, Martin ;
Treschan, Tanja A. ;
Goerlinger, Klaus ;
Peters, Juergen .
ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) :749-754
[9]   Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells [J].
Blank, M ;
Shoenfeld, Y ;
Tavor, S ;
Praprotnik, S ;
Boffa, MC ;
Weksler, B ;
Walenga, MJ ;
Amiral, J ;
Eldor, A .
INTERNATIONAL IMMUNOLOGY, 2002, 14 (02) :121-129
[10]  
Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1564